ARQT
Arcutis Biotherapeutics Inc
Mentions (24Hr)
0.00% Today
Reddit Posts
$ARQT during the weekend two pieces of great news; short interest 27 %
ARQT got FDA PDUFA approval on Friday After-Hours
ARQT got FDA PDUFA approval Friday after-hours…
$ARQT “Analysis” •PDUFA December 16 2023 •PDUFA July 07 2024 •Cash and equivalents: $228.0 million •25% Short Interest •9 Days to Cover
Mentions
ARQT? I saw this one just a bit ago: Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus
Loss aversion is a key concept in behavioural economics and psychology, describing how people tend to feel the pain of losses more intensely than the pleasure of equivalent gains. What you are feeling is completely normal. When your investment goes from $10000 to $20000 then back to $15000, you feel like you’ve lost $5000 rather than gain $5000. Recognise your psychological biases when investing and learn from your mistakes. I’ve learnt this the hard way too. Nowadays I avoid biotech companies and binary events such as FDA approvals and earnings plays. Except ARQT. That’s up 80% since I invested. lol
ARQT, lets ffreeakking gooooo
$ARQT's eczema cream is due to be sold in October. Target Price = $23.38
I'll play I've got 7 GOOG MO AMSC AQST ARQT JOBY QS not in any particular order
I like the JHX and ALB plays. I know nothing about ARQT though. I will look into it. Thanks for posting!
Thoughts on ARQT? Just got FDA approval
I’m the biotech regard who cried the other day about RFK Today got my bounce. Was literally in margin call at open. TGTX (ms drug called briumvi) got wonderful news midday about Roche failing its most recent trial for its MS drug. Clear skies ahead Also just got news in ARQT that they stayed patent litigation for its future blockbuster psoriasis drug. Spiking hard. I am now +120k since pre market
Actually, 59% placebo isn’t a red flag — it’s common in dermatology trials. Topical “placebos” often use the same base cream (just without the drug), which can still hydrate and calm the skin. That alone boosts response rates. The fact that ARQT still hit 80.1% vs 59.2% with a p-value < 0.0001? That’s not weak — that’s clinical strength. Beating a high-response placebo by 20%+ in derm is legit impressive. High placebo = tough benchmark. ARQT still crushed it.
Despite carrying around $204M in debt, $ARQT’s financial positioning actually looks solid — and bullish. They originally secured a $225M term loan from SLR Capital to fund product development and launches, but here’s the kicker: in Q4 2024, they already paid off $100M of that. That’s a strong signal they’re confident in their revenue stream and cash flow. Companies under stress don’t drop nine-figure repayments — winners with a roadmap do. Add in the fact that they’ve still got $229M in cash and can access another $100M if needed (total liquidity ~$329M), and you’ve got a company with options — and control. That kind of balance sheet flexibility gives them room to fund launches, scale sales, and navigate bumps without leaning hard on dilution. In a biotech world where most small caps are sprinting on fumes, ARQT looks like it showed up to the marathon with an oxygen tank and an energy drink.
ARQT trading like a buyout leak
I’ve been in TGTX since the teens. I hold massive position in ARQT. And holding huge amount of SWTX which is currently negotiations a buyout with Merck kgaA Waiting to free up $$ to add VRNA MDGL
You can find these filings on the SEC filings site. It takes some practice to read the filings. Or there are sites like Whale Wisdom and others. Some are free and some charge a fee. Right now, I am lucky enough to have access to a Bloomberg at work so just that. PHAT, ARQT are my faves right now. I want CNTA to come back to $12.
I’m over 100% long term gains on TGTX. Large positions in ARQT, RARE, SWTX, OCUL and ASND. Speculative position in ATYR (up 20%) already.
Tell me if I’m wrong. But $ARQT looks good today…
$ARQT looking for breakout today.
Sorry very delayed! KODK > Eastman Kodak Company (KODK) is experiencing heightened volatility, with recent pre-market activity suggesting speculative interest. The stock has surged significantly above its 65-day average volume, indicating strong buying pressure. Technical indicators show an overbought condition with a 14-day RSI of 76.16, suggesting potential for a pullback. The MACD histogram is positive, supporting bullish momentum, but caution is advised due to the high RSI. Given the broader market's cautiously optimistic sentiment, KODK may continue to see upward movement, albeit with potential volatility. For today's session, consider a long position with an entry around $7.30, targeting $8.00 and $8.50, with a stop loss at $6.80. Confidence in reaching the first target is moderate due to speculative dynamics, while the second target carries lower confidence given potential resistance and market consolidation. MNMD > Mind Medicine (MNMD) is currently experiencing bullish momentum, driven by positive sentiment around its Phase 3 trials and potential regulatory changes in psychedelic therapies. The stock has seen a significant price increase, with technical indicators like the 10-day SMA at $7.63 and the 8-day EMA at $7.77 supporting upward movement. The RSI levels are moderately high, indicating strong buying pressure but also suggesting caution for potential overbought conditions. Recent trading volumes are below the 65-day average, which could imply limited liquidity but also potential for a breakout if volume increases. Given the broader market's cautiously optimistic phase, MNMD may benefit from the tech sector's strength, though geopolitical risks could introduce volatility. For today's session, consider a long position with an entry around $8.20, targeting $8.50 as the first price target and $8.70 as the second, with a stop loss at $7.90. Confidence in reaching the first target is moderate due to current momentum, while the second target carries lower confidence given potential market headwinds. ARQT > Arcutis Biotherapeutics, Inc. (ARQT) is showing signs of a potential bullish reversal, supported by a 6.9% price increase to $11.51 and a high "squeezability" score of 60%, indicating the possibility of a short squeeze if the price breaks above $13.2. The technical indicators are strong, with the RSI levels suggesting overbought conditions, but the MACD histogram remains positive, indicating continued upward momentum. The recent price target update from Mizuho adds to the bullish sentiment, although caution is advised due to speculative nature of short squeezes. The broader market's cautiously optimistic phase, with SPY and QQQ trending upwards, supports ARQT's potential for gains, especially as technology sectors outperform. For today's trading session, consider a LONG position with an entry around $11.50, targeting $12.80 first and $13.20 second, with a stop loss at $10.90. Confidence in reaching the first target is moderate due to current momentum, while the second target depends on breaking key resistance levels. Keep an eye on any catalysts or news that could impact ARQT's trajectory, as market dynamics remain fluid.
Idk go look it up if he’s talked about them. But I personally trimmed 1/3 off my vktx and loaded more ARQT and OCUL today (still holding 2400 shares though)
ARQT expiry in 2 weeks, far OTM, just coinflip calls or puts. Id go puts since theres more downside potential at the moment.
I almost did the same thing with ARQT, it's up 15% this week
Biotech ARQT bought 2.98 12/18/24 now 8.88, INSM bought 24.68 5/21/24 48.06 now 48.06
ARQT time to rally back to $12 my guy - need to see some explosive sales of Zoryve and revised guidance 
My last quarter DD on ARQT. I think if anything has changed, I'm less worried about the cons and the pros are just as strong as before. I'm 10k in shares and 2k in calls. [https://www.reddit.com/r/wallstreetbets/comments/1ay27g7/arqt\_earnings\_the\_company\_youve\_never\_heard\_of/?utm\_source=share&utm\_medium=web3x&utm\_name=web3xcss&utm\_term=1&utm\_content=share\_button](https://www.reddit.com/r/wallstreetbets/comments/1ay27g7/arqt_earnings_the_company_youve_never_heard_of/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button)
any idea about ARQT (Arcutis Biotherapeutics)? ER in on Tuesday.
ARQT bout to go crazy on Tuesday
ARQT Started investing at $2, right now sitting on $11 and going up, gem of a find
ARQT, i think there is more room to go up
I’m just small fry but a little while back I bought around $1000 of ARQT at $2 a share, it’s up over $11.75 now. I’m pretty proud of that come up.
I wrote a text that went with this but I a regard and the text isn't showing up! Total degenerate and opened a T-IRA with intent to beat the S&P. Started with 1k and yolo'd into $FNGU. Made some nice trades in LETF but mainly was flat by year end. Big gamble in 2024. Mainly Biotechs! Big wins on $ALDX $ARQT $FATE and $HOWL. Had made wins and losses trying to scalp $LABU. While I swore off biotech by the end of 2021, November CPI of 2023 was a big signal of it's recovery! $XBI and $LABU are giving trading blows and matching with AI and Silicon!
ARQT, call options any strike any day basically
>ARQT This turned out to be a good tip!
ARQT upgraded to $16 current price $10.70
Sounds like my puts today on ARQT
ban betting myself !banbet ARQT $13 1w
Debating on tying up on ARQT straddles with earnings today
ARQT for the win!! earnings is a BEAT! looking for 15-20$
How do you guys feel about ARQT. I think a straddle might be the best option with most of it in calls
Good week: U puts, ARQT puts, BMBL puts, ADSK calls
From what I've seen, the shareholders on ARQT don't trade with the market. When SPY was up, but ARQT news was bad it was 60 days of straight red, meanwhile the last three months have been 90 days green even on overall market down days. So, if it's green day I'll sell immediately. If it's red I'm selling at expiration (3/15) or exercising my contracts to exit position. I'll update here in the post either way.
Look at ARQT calls. They are Soo juicy
Look at ARQT calls. They are Soo juicy
$2 to $10 in 3 months. My ARQT calls are literally taking my soul to heaven 
Up 700% on ARQT calls 
Unless I missed something, I don't see anything directly in the weight loss area for either ARQT's or LXRX's pipelines (LXRX does have a diabetes drug in Phase 3, but it is listed as for type 1, so not really adjacent to my target like type 2 diabetes drugs some other weight loss drug companies also have or are developing). They do seem to be similar in some ways such as market cap and stage of some of their main products, but I can't really comment on the market potential of either since I'm not in the pharma industry and have no knowledge on the markets for most of the drugs in their pipelines. My focus is the gold rush for weight loss drugs (one specifically approved for treating obesity). My play is basically hoping the stock market will eventually wake up to the potential that ALT's weight loss drug can be competitive against other drugs in that space both by having good efficacy in weight reduction and in having additional verified benefits - if it also eventually gets approval for treatment of NASH, that could make their drug a preferred choice for weight loss (pipe dream would be insurance companies having to pay for such treatment so all the overweight people can just say they need it for liver health and lose weight in the process, though that scenario of market dominance is a ways off from now).
I’m curious what your thoughts are on similar stocks like ARQT or LXRX?
ARQT calls TSLA puts PLTR calls This has been a year to remember
Anyone else get onboard ARQT after the PDUFA in December?
Any opinions on ARQT upside targets? Had high short interest, built a base and running now, not sure if this is a strong short squeeze candidate?
ARQT, CMPS, DNN & URNM are straight up carrying my portfolio this year
Xom and sunoco both upgraded. Look at ARQT. Just went to market with FDA approved drug. This is not hype darn thing up 25% in a couple days. Target 12 at 4.65 right now. Just an FYI.
My picks are biotech, OCUL, ARQT, GOSS, HROW, LRMR
Has any1 seen ARQT?? Been going up like CRAAZY
ARQT and PHAT. Two major buyout candidates. Both have blockbuster approved agents. Trading for a massive discount right now.
ARQT looks to be undervalued, currently has 2 FDA approved drugs with 1 already generating revenue and the other expected to be in pharmacies in late January. There is also another FDA approval due July. Currently trading for / at the price before FDA approval last week and has large short interest. New innovation in the seborrheic dermatitis market (newest drug in 20 years) with estimated 10 million patients in US alone. Market research shows 9 in 10 patients open to new treatments which means large potential for revenue growth. TLDR : ARQT undervalued imo and has 2 approved fda drugs and 1 yet to be approved in July.
I love this ARQT consolidation / accumulation
Sell the news ARQT and QURE, twice, on positive data, crooks ffs
What in the fuck is happening with ARQT
ARQT 🧐, looking interesting
27% short of float on ARQT, up 30%, where short squeeze!?!
ARQT will pop, VOR and QURE possibly later in the week
$ARQT has some legs with FDA approval
Sure am. ARQT is doing better than it was the day after approval lol. BLUE will be fun. That's a buy and hold for me.
You are talking about Bluebird boi? Hows ARQT?
Buy ARQT puts today! They're going to get an FDA decision on a new drug tomorrow. Clinical trials have been amazing and the drug works very well. Problem for them is their main manufacturer Interquim has never had a good FDA inspection and there's a 50/50 chance the FDA poo poos the drug based on the manufacturing facility inspection.
ARQT to the moon on Friday hopefully, so long as the FDA approves their new psoriasis drug. First bullish position I've had in months!
Tomorrow is all about sitting back and watching the puts rise. End of July will be more interesting with ARQT calls.
I am a bot. You submitted a picture of a banned ticker, ARQT. This check will fire if you included unnecessary pictures that have bad phrases or a bad crop with news about cryptocoins, for example. Repost with the useless pictures omitted if you did that. Yell at /u/zjz if it's above 1.5 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.